Skip to content
Screener

UroGen Pharma URGN Gross margin

Discontinued — last reported Q2 '21

Gross margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
70.2%-0.1pp
Pfizer logo
PfizerPFE
73.2%+1.1pp
Johnson & Johnson logo
Johnson & JohnsonJNJ
67.9%0.0pp
Merck & Co. logo
Merck & Co.MRK
73%-3.6pp
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
99.3%-0.5pp
Nuvation Bio logo
Nuvation BioNUVB
54.3%+39.5pp

Other financials

Income statement

See full
Revenue$72.5M+199%
Net income-$14.4M+71.3%

Balance sheet

See full
Cash & equivalents$79.1M-14.8%
Total debt$197.5M+55.0%
Total equity-$132.4M-41.8%
Total assets$252.6M+21.0%

Cash flow

See full
Operating cash flow-$33.0M+17.1%
CapEx$60.0K-57.4%
Free cash flow-$33.1M+17.3%

Valuation

See full
Market cap$2.22B+140%
Enterprise value$2.34B+144%
P/S11.8×+2.0×

Profitability

See full
Operating margin-329.7%—
Net margin-51.7%-21.0pp
FCF margin-84.3%-22.2pp

Returns & leverage

See full
Return on equity-211.6%—
Debt / equity4.8×—
Current ratio3.8×-0.3×

Where this comes from

Calculated from UroGen Pharma’s reported figures.

gross profit/total revenue=89.7%

Based on trailing twelve months.

The source filing: UroGen Pharma’s 10-Q, filed August 4, 2021. Open the filing →

Filed
Aug 4, 2021, 8:09 AM EDT
Fiscal quarter
Q2 FY2021
Calendar quarter
Q2 2021
Accession
0001564590-21-040510

FAQ

What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.